Buprenorphine

Major

Buprenorphine Desipramine Norpramin Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Deslorelin Explained An increased risk of QT interval prolongation Details Buprenorphine Desvenlafaxine Pristiq Explained An increased risk of serotonin syndrome Details Buprenorphine Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Buprenorphine Dexamethasone Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Dexmedetomidine Dexased Explained Increased risk of cardiac arrhythmias and increased risk of CNS depression Details Buprenorphine Dextroamphetamine Dexedrine Explained An increased risk of serotonin syndrome Details Buprenorphine Dextromethorphan Delsym Explained An increased risk of serotonin syndrome Details Buprenorphine Dezocine Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome and respiratory depr... Details Buprenorphine Diacetylmorphine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Diazepam Diastat Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Diazoxide Proglycem Explained Reduced efficacy of diuretics Details Buprenorphine Dibenzepin Explained An increased risk of serotonin syndrome Details Buprenorphine Dichloralphenazone Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Dicyclomine Bentyl Explained An increased risk of paralytic ileus Details Buprenorphine Difenoxin Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Dihydrocodeine Explained Reduced analgesic effect or precipitation of withdrawal symptoms and an increased risk of serotonin syndrome Details Buprenorphine Diltiazem Cardizem Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Dimenhydrinate Airmit Explained An increased risk of paralytic ileus Details Buprenorphine Diphenhydramine Banophen Explained An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Diphenoxylate Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Dipyrone Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Disopyramide Norpace An increased risk of QT interval prolongation Details Buprenorphine Dofetilide Tikosyn An increased risk of QT interval prolongation Details Buprenorphine Dolasetron Anzemet An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Domperidone Explained An increased risk of QT interval prolongation Details Buprenorphine Donepezil Adlarity Explained Reduced seizure threshold and increased risk of QT prolongation Details Buprenorphine Dordaviprone Explained An increased risk of QT interval prolongation Details Buprenorphine Doxepin Prudoxin Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome, an increased risk of paralytic ileus and a... Details Buprenorphine Doxylamine Aldex AN Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Droperidol Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Duloxetine Explained An increased risk of serotonin syndrome Details Buprenorphine Duvelisib Copiktra Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Ebastine Explained An increased risk of QT interval prolongation Details Buprenorphine Efavirenz Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation Details Buprenorphine Elagolix Orilissa Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Eletriptan Relpax Explained An increased risk of serotonin syndrome Details Buprenorphine Encorafenib Braftovi Increased risk of QT interval prolongation Details Buprenorphine Enflurane Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Entrectinib Rozlytrek An increased risk of QT interval prolongation Details